JP Morgan analyst Anupam Rama initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rati

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks T

MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology compan

Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targ

MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company

Brandywine Managers LLC acquired a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the secon

Guggenheim analyst Brad Canino maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price t

Citizens analyst Silvan Turkcan reiterates Celcuity (NASDAQ:CELC) with a Market Outperform and ma

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Celcuity (NASDAQ:CELC) with a B

Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 incl

Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday

Celcuity Inc (NASDAQ:CELC) reported better-than-expected Q2 losses of $1.07 per share. Analysts are

Stifel analyst Stephen Willey maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price ta

Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target

Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript

Celcuity NASDAQ: CELC said it remains on track to begin commercial shipments of REVTORPYK, its gedat

On Thursday, Celcuity (NASDAQ:CELC) discussed second-quarter financial results during its earnings c

Celcuity (NASDAQ:CELC) reported quarterly losses of $(1.07) per share which beat the analyst consens

MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company

California State Teachers Retirement System lifted its holdings in Celcuity, Inc. (NASDAQ: CELC) by

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biot

NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered L

The law firm of [url="]Kirby McInerney LLP[/url] reminds investors of its investigation on behalf of

NEW YORK--(BUSINESS WIRE)---- $CELC #classaction--The law firm of Kirby McInerney LLP reminds invest

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $CELC--CELC Investors Have Opportunity to Join Celcuity Inc. Fraud

CELC Investigation: Kessler Topaz Meltzer and Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Inv

RADNOR, Pa., July 31, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nati

Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targ

Gainers China Pharma Holding (AMEX:CPHI) shares moved upwards by 67.6% to $1.03 during Wednesday&#3

Citizens analyst Silvan Turkcan maintains Celcuity (NASDAQ:CELC) with a Market Outperform and rai

Top Wall Street analysts changed outlook on top names. See all changes, including upgrades/downgrade

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Bu

Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechn

Craig-Hallum analyst Alexander Nowak maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the p

Wells Fargo analyst Eva Fortea Verdejo maintains Celcuity (NASDAQ:CELC) with a Overweight and low

Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Bu

Celcuity Inc. (NASDAQ:CELC) ("Celcuity" or the "Company"), a clinical-stage biotechn

Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-muta

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of ta

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of ta

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on the development of ta

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Bu

Celcuity expands VIKTORIA-2 to endocrine-sensitive breast cancer patients and advances injectable ge

Wells Fargo analyst Eva Fortea Verdejo maintains Celcuity (NASDAQ:CELC) with a Overweight and rai